Wissenschaftl. Titel | A randomized, multicenter 28 week study to compare the efficacy and safety of combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) with a lifestyle intervention to Cosentyx therapy alone in adult patients with moderate to severe plaque-type psoriasis and concomitant metabolic syndrome, followed by a 28 week extension period |
Erkrankung |
Haut:
Schuppenflechte (Psoriasis)
|
weitere Prüfzentren | |
Kurzprotokoll | Kurzprotokoll |
Links | Zu den Ein- und Ausschlusskriterien |
erstellt 26.11.2020 Student Studienregister
geändert 19.10.2022 Student Studienregister